4. SD of BP at baseline vs endpoint in trials with DBP entry criteria.
ACE Inhibitor | Placebo | ||
Weighted mean SD of SBP | At baseline (SD) | 14.8 (3.0) | 14.9 (2.8) |
At endpoint (SD) | 16.6 (3.1) | 16.8 (3.0) | |
t‐test | baseline vs endpoint | p = 0.06 | p = 0.05 |
Weighted mean SD of DBP | At baseline (SD) | 5.1 (1.5) | 5.1 (1.6) |
At endpoint (SD) | 9.0 (1.7) | 8.9 (1.8) | |
t‐test | baseline vs endpoint | p < 0.0001 | p < 0.0001 |